Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fipravirimat - ViiV Healthcare

Drug Profile

Fipravirimat - ViiV Healthcare

Alternative Names: 3640254; BMS 986197; GSK-254; GSK-3640254

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer GSK; ViiV Healthcare
  • Class Antiretrovirals
  • Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 03 Mar 2024 Fipravirimat is still in phase II trials for HIV infections in USA, Argentina, Canada, France, Germany, Italy, Portugal, Russia, South Africa, Spain and Switzerland (ViiV healthcare pipeline, March 2024)
  • 03 Mar 2024 Pharmacodynamics and Efficacy data from a phase II DOMINO trial in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI-2024)
  • 08 Sep 2023 ViiV Healthcare terminates the phase IIb DYNAMIC trial for HIV infections (Combination therapy, Treatment-naïve) in US, Argentina, Canada, France, Germany, Italy, Portugal, Puerto Rico, South Africa and Spain (PO), due to company strategy for portfolio progression (NCT04900038)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top